Report Details:
15 Companies Covered
128 Pages
Insulin Syringe Market Highlights
The Global Insulin Syringes Market size was valued at USD 1.90 Billion in 2025, and the market is projected to grow from USD 1.99 Billion in 2026 to USD 3.00 Billion by 2035, registering a CAGR of 4.70% during the forecast period 2026–2035.
This growth is attributed to a number of factors, including the rising prevalence of diabetes, an aging population, and increasing disposable income. According to the Diabetes Atlas 2021, there were 206 million people suffering from diabetes in the Western Pacific, 90 million in Southeast Asia, 73 million in the Middle East and Africa, 61 million in Europe, 51 million in North America and the Caribbean, and 32 million in South and Central America.
Furthermore, technological advancements are also playing a role in the growth of the market, with the development of new features such as safety syringes and pre-filled syringes. These advancements are making insulin syringes more user-friendly and convenient for patients. Moreover, emerging markets are also expected to be a key driver of growth in the coming years. The rising prevalence of diabetes in these markets, coupled with increasing government support for diabetes care, is creating a significant growth for insulin syringe manufacturers.
However, the economic and regulatory challenges, such as rising costs and stricter regulations, are limiting the market's growth. Moreover, growing demand for safety syringes because safety syringes are designed to prevent needlestick injuries, which are a major concern for healthcare professionals and patients alike, is creating lucrative growth opportunities for the market during the forecast period.
MRFR recognizes the following companies as the key players in the global insulin syringe market— Terumo Corporation (Japan), Cardinal Health, Inc. (US), Beckton and Dickinson Company (US), Nipro Medical Corporation (US), Medline Industries (US), Arkray Inc. (India), Trividia Health Inc. (US), Ultimed Inc. (US), Hindustan Syringe and Medical Device, Ltd. (India), Shanghai Kindly Enterprise Development Group Co., Ltd (China), and others.
Segment Analysis
The global insulin syringe market has been segmented based on syringe size, indication, and end user.
On the basis of type, the market is segmented into 3/10 CC syringes (0.3 ml), 1/2 CC syringes (0.5 ml), 1 CC syringe (1 ml), and others. The 1CC syringe (1 ml) segment held the largest market share in 2022 due to its several advantages over larger syringes, making them a popular choice for an insulin injection. Here are some key advantages such as accurate dosing, convenience and portability, reduced risk of needlestick injuries, and cost effectiveness.
Based on indication, the global insulin syringe market has been segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment dominated the market in 2022 and was the fastest-growing segment during the forecast period. This is due to increasing incidences of type 2 diabetes which increases the demand for insulin syringes. As per the Diabetes Atlas 2022, there are 476 million indigenous people in 90 countries, and 10% of them suffer from type II diabetes.
On the basis of end users, the global insulin syringe market has been segmented into hospitals and clinics, homecare settings, and others. Hospitals and clinics accounted for the largest market share, and the homecare settings segment was the fastest-growing segment during the forecast period owing to the increasing incidences of both types of diabetes in emerging regions and the rising adoption of technologically advanced syringes in regions such as North America and Europe.
Regional Analysis
The global insulin syringe market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe insulin syringe market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The insulin syringe market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World insulin syringe market comprises the Middle East, Africa, and Latin America.
The North America insulin syringe market held the largest market share in 2022 due to factors such as the increasing incidence of diseases that may increase the chance of diabetes, including obesity. According to the World Population Review, the US has the 12th highest rank for obesity, and the ratio is different among all districts in the US due to the same dietary, environmental, and cultural factors.
Furthermore, the presence of important players such as Cardinal Health, Inc. (US), Beckton and Dickinson Company (US), Nipro Medical Corporation (US), Medline Industries (US), Trividia Health Inc. (US), and Ultimed Inc. (US). Moreover, Beckton and Dickinson Company (US) is a renowned player whose products are highly in demand, including the BD Glide with TBL U40 Insulin Syringe.
Moreover, the European insulin syringe market shows notable growth during the forecast period, i.e., 2023–2022. This is due to the growing prevalence of diabetes diseases in the region, which will create growth opportunities for the insulin syringe market. According to International Diabetes Federation (IDF) estimates, the absolute amount of diabetes in the EU will increase from around 33 million in 2010 to 38 million in 2030.
Furthermore, the Asia-Pacific insulin syringe market is representing the highest CAGR during the forecast period owing to higher adoption of sedentary lifestyle, increasing incidences of both types of diabetes, growing geriatric population. According to the Asia-Pacific Report on Population Ageing 2022, there would be around 670 million people in Asia-Pacific aged 60 or older in 2022.
Additionally, the Middle East, Africa, and Latin America regions comprised the rest of the world. The region accounted for the lowest market share in the insulin syringe market due to the low adoption of technologically advanced insulin syringes. However, governments in the Middle East &Africa (MEA) region are investing heavily in healthcare infrastructure, leading to improved access to diagnosis and treatment for diabetes. Furthermore, emerging markets like Nigeria, South Africa, and Kenya are expected to be key drivers of market growth.
Key Findings of the Study
- Hospitals and clinics held 51.0% share in 2025, anchored by institutional procurement contracts and inpatient insulin management needs
- Home-care settings are rising at a 5.60% CAGR, reflecting patient preference for self-administration and telehealth-guided dosing
- North America led with 43.0% revenue share in 2025, backed by a robust reimbursement infrastructure
- Asia-Pacific is on track for a 5.55% CAGR, driven by national diabetes control programs in India and China
